\
&
Contact us
Published on | 5 months ago
Last updated on | 3 months ago
Ria.debreucker@vlaio.be
Signing a Consortium Agreement is most of the time mandatory for European Projects. The CA should be installed before signing the Grant Agreement.
The consortium agreement represents how the members of the consortium will be working on the project. While the Grant Agreement (GA) is signed between the consortium (represented by the coordinator) and the European Commission or granting authority, the CA governs the relationship between the beneficiaries themselves.
It should handle:
In practise many Consortium Agreements are based on the DESCA-models though there are other models available. DESCA provides models for both Lump sum and Actual Cost based grants and an edition that for the inclusion of Associated Partners.
Some partnerships in specific sectors provide CA-models taking into account specific approaches widely used in the sector (eg IHI).
Even when starting from these widely used models you should:
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
The Horizon2020 project BEAT-AF brings together 9 European renowned clinical centres in France, Belgium, Czechia, Germany and Austria. Together, the consortium strives to revolutionize Atrial Fibrillation (AF) treatment through catheter ablation and contribute to decrease the huge burden of AF in Europe. The BEAT-AF project kicked off in 2021 and will run until 2026. The department of electrophysiology of the AZ Sint-Jan Hospital in Bruges is partner in the project and has so far contributed to the pre-clinical development, the first in man studies and first registries of the revolutionary AF treatment put forward by the consortium. The first pilot studies show that the treatment is safe, effective and efficient.